glp 1 for liver GLP-1 Receptor Agonists in Non-Alcoholic Fatty Disease: Current Evidence and Future Perspectives Current Status of Glucagon-like Peptide-1

AF has also received research funding from Eli Lilly and Viking

The problem is that these Glucagon-like peptide-1 (GLP-1) drugs were initially approved to treat type 2 diabetes, and later received approval as weight-loss medications, researchers said

Yet public opinion toward these medications remains divided

In contrast, Wegovy may cause inflammation of the pancreas (pancreatitis), gallbladder problems, and thyroid tumors

The formazan is then solubilized, and the concentration determined by optical density at 570 nm

doi: 10.3389/fendo.2024.1520313 Received 31 October 2024 Accepted 26 December 2024 Published 21 January 2025 Volume 15 - 2024 Edited by Joseph M